Monoclonal Antibody Infliximab Biosimilar from Germany
A biotechnologically produced chimeric monoclonal antibody targeting TNF-alpha, used to treat inflammatory conditions like Crohn's disease. It qualifies under HTS 3002.12.0090 as an immunological product (per chapter note) obtained via biotech processes from blood fraction-inspired cell cultures. This covers modified proteins regulating immune processes.
Duty Rate — Germany → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Submit IND or BLA documentation proving therapeutic immunological function to justify Chapter 30 classification
• Monitor for biotech origin certification; declare purity levels >95% to avoid Chapter 35 peptide reclassification